Matinas BioPharma Holdings, Inc.
MTNB
$0.18
$0.000.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -100.00% | -- | -- |
| Gross Profit | -- | -- | 100.00% | -- | -- |
| SG&A Expenses | -15.35% | 4.03% | -3.73% | -26.38% | -25.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.35% | -0.51% | -60.38% | -64.00% | -68.54% |
| Operating Income | 15.35% | 0.51% | 60.38% | 64.00% | 68.54% |
| Income Before Tax | 74.72% | -16.00% | 77.54% | 64.16% | 8.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.72% | -16.00% | 77.33% | 64.16% | 8.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.72% | -16.00% | 77.33% | 64.16% | 8.29% |
| EBIT | 15.35% | 0.51% | 60.38% | 64.00% | 68.54% |
| EBITDA | 14.78% | 0.00% | 59.56% | 63.23% | 68.26% |
| EPS Basic | 79.92% | 7.86% | 81.64% | 53.39% | 10.09% |
| Normalized Basic EPS | 34.96% | 21.79% | 63.52% | 66.80% | 67.43% |
| EPS Diluted | 79.92% | 7.86% | 81.64% | 53.39% | 10.09% |
| Normalized Diluted EPS | 34.96% | 21.79% | 63.52% | 66.80% | 67.43% |
| Average Basic Shares Outstanding | 25.93% | 25.93% | 23.47% | 7.90% | 2.01% |
| Average Diluted Shares Outstanding | 25.93% | 25.93% | 23.47% | 7.90% | 2.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |